Last reviewed · How we verify

Sevoflurane intravenous anesthesia

The Cleveland Clinic · Phase 3 active Small molecule

Sevoflurane acts as a general anesthetic by modulating the activity of the GABA_A receptor, leading to a decrease in neuronal excitability.

Sevoflurane acts as a general anesthetic by modulating the activity of the GABA_A receptor, leading to a decrease in neuronal excitability. Used for General anesthesia for surgical procedures.

At a glance

Generic nameSevoflurane intravenous anesthesia
Also known asSevoflurane
SponsorThe Cleveland Clinic
Drug classVolatile anesthetic
TargetGABA_A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Sevoflurane is a volatile anesthetic agent that exerts its effects by enhancing the activity of the inhibitory neurotransmitter GABA at the GABA_A receptor. This results in a decrease in neuronal excitability, leading to a loss of consciousness and analgesia. The exact mechanism of action is not fully understood, but it is thought to involve the modulation of GABA_A receptor subunits and the inhibition of excitatory neurotransmitter release.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: